1 – 9 of 9
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Quality assessment of radiotherapy in the prospective randomized SENOMAC trial
(
- Contribution to journal › Article
- 2023
-
Mark
Population-based prognostic instrument (SweMR 2.0) for melanoma-specific survival - An ideal tool for individualised treatment decisions for Swedish patients
(
- Contribution to journal › Article
-
Mark
ASO Visual Abstract : Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (> 4 mm)
(
- Contribution to journal › Published meeting abstract
-
Mark
Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (> 4 mm)
(
- Contribution to journal › Article
- 2021
-
Mark
Surgery of metastatic melanoma after systemic therapy–the SUMMIST trial : study protocol for a randomized controlled trial
(
- Contribution to journal › Letter
-
Mark
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
(
- Contribution to journal › Article
- 2020
-
Mark
The generalisability of randomised clinical trials : an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer
(
- Contribution to journal › Article
- 2019
-
Mark
ASO Author Reflections : Effects of the Updated AJCC Classification for Patients with Stage III Melanoma
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden
(
- Contribution to journal › Article